Michael Bell

Michael Bell is an experienced finance professional with a strong focus on the life sciences sector. Currently serving as Managing Director at Mount Morris Advisors since January 2016, Michael provides independent advice and operational support to early-stage private companies. In addition, Michael holds the position of Consulting Chief Financial Officer at ImmunoMet Therapeutics, Inc. and previously served as Consulting Head of Finance at Relmada Therapeutics, Inc. From July 2005 to December 2014, Michael was the Senior Vice President at Seaview Securities, overseeing private placement financings and M&A for life science companies. Michael’s earlier roles include Vice President at Marsh & McLennan and Verizon Communications, where responsibilities involved conducting due diligence on acquisition targets, and auditing at PricewaterhouseCoopers. Michael earned an MBA in Finance from Columbia Business School, an MSc in International Relations from The London School of Economics and Political Science, and a BA in International Relations from Brown University.